

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-152/S-006

APPROVAL LETTER



NDA 20-152/S-006

Bristol-Myers Squibb Company
Attention: Jay K. Gunther, Ph.D.
Director Regulatory Science
Five Research Parkway
Wallingford, CT 06492

Dear Dr. Gunther:

Please refer to your supplemental new drug application dated August 8, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Serzone (nefazodone hydrochloride) 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg Tablets.

Reference is also made to your amendments dated October 6, 1998, and May 26, 2000.

We additionally refer to Agency letters dated March 27, 1998, and March 29, 2000.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted May 26, 2000-Label Code 1017710A8). Accordingly, this supplemental application is approved effective on the date of this letter.

This supplemental new drug application provides for the following revisions to product labeling:

1. The addition of "carbamazepine" to the list of drugs contraindicated with nefazodone in the **CONTRAINDICATIONS** section of labeling.
2. A new subsection in the **PRECAUTIONS** section entitled **Interaction with Carbamazepine**.
3. Revisions to the **Pharmacokinetics-Protein Binding** and the **Precautions-Drug Interactions** sections based upon information derived from *in vivo* studies to examine the effects of nefazodone on the pharmacokinetics of warfarin, fluoxetine, phenytoin, desipramine, lithium, carbamazepine, and theophylline.

Additionally we note that carbamazepine was not included in the list of drugs which should not be taken with Serzone in the **PRECAUTIONS-Information for Patients-Concomitant Medication** section of labeling. We request that carbamazepine be added to this list at the next printing of Serzone labeling.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

NDA 20-152/S-006

Page 2

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Paul David, R.Ph., Regulatory Project Manager, at (301) 594-5530.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

NDA 20-152/S-006

Page 3

cc:

Archival NDA 20-152

HFD-120/Div. File

HFD-120/P.David

HFD-120/RKatz/T.Laughren/E.Hearst

HFD-860R.Baweja/H.Zhao

HF-2/MedWatch (with labeling)

HFD-002/ORM (with labeling)

HFD-101/ADRA (with labeling)

HFD-104/Peds/V.Kao (with labeling)

HFD-104/Peds/T.Crescenzi (with labeling)

HFD-40/DDMAC (with labeling)

HFI-20/Press Office (with labeling)

HFD-400/OPDRA (with labeling)

HFD-613/OGD (with labeling)

HFD-095/DDMS-IMT (with labeling)

HFD-810/DNDC Division Director

DISTRICT OFFICE

7/17/00

filename:SERZONE LABELING APPROVAL LETTER SLR-006.DOC

APPROVED (NDA 20-152/S-006)

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-152/S-006

APPROVABLE LETTERS



NDA 20-152/S-006

Bristol-Myers Squibb Company
Attention: Jay K. Gunther, Ph.D.
Director, Worldwide Regulatory Affairs
5 Research Parkway, P.O. Box 5100
Wallingford, Connecticut 06492-7660

Dear Dr. Gunther:

Please refer to your supplemental new drug application dated August 8, 1996, received August 9, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Serzone (nefazodone hydrochloride) Tablets.

We acknowledge receipt of your submission dated October 6, 1998. Your submission of October 6, 1998 constituted a complete response to our March 27, 1998 action letter.

This supplement proposes the following changes:

- The revision of the **Pharmacokinetics-Protein Binding** and the **Precautions-Drug Interactions** sections based upon information derived from *in vivo* studies to examine the effects of nefazodone on the pharmacokinetics of warfarin, fluoxetine, phenytoin, desipramine, lithium, carbamazepine, and theophylline.

We note Agency agreement with all of your proposed revisions except for the placement of the carbamazepine interaction in which the Agency requested, in our letter of March 27, 1998, that this interaction be placed in the **Contraindications, Warnings, and Precautions** sections of labeling.

Your submission of October 6, 1998, provides for your rationale, listed below, that the _____

We have completed our review of your response, and we still believe that the labeling changes, as outlined in our March 27, 1998 letter, should be made verbatim.

We concur that it would be unusual to contraindicate the use of a drug because it reduces almost to undetectable levels the presence of another drug. It is not a safety problem in the usual sense. However, the lack of effective antidepressant effect represents a hazard, and, as noted in your October 6, 1998 submission, you seem to agree that the 2 drugs should not be used together. —

For the above reasons, we believe that nefazodone should be contraindicated with carbamazepine. Therefore, we are requesting that you submit final printed labeling providing for your proposed changes as well as the revisions outlined in the Agency letter dated March 27, 1998 within 2 months from the date of this letter.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

This product may be considered to be misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with these changes prior to approval of this supplemental application.

If you have any questions, call Paul David, R.Ph., Regulatory Management Officer, at (301) 594-2850.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

NDA 20-152/S-006

Page 3

cc:

Archival NDA 20-152/SLR-006

HFD-120/Div. Files

HFD-120/PDavid

HFD-120/RKatz/TILaughren/Ehearst

HFD-860/RBaweja/HZhao

DISTRICT OFFICE

3-16-00

filename:SERZONE\NDA\10-6-98 AE LETTER SLR-006

APPROVABLE (AE)

NDA 20-152/S-006

MAR 27 1998

Bristol-Myers Squibb Company
Attention: Jay K. Gunther, Ph.D.
5 Research Parkway
P.O. Box 5100
Wallingford, Connecticut 06492-7660

Dear Dr. Gunther:

Please refer to your August 8, 1996, supplemental new drug application (NDA) for Serzone (Nefazodone Hydrochloride) tablets.

Supplemental application S-006 provides for revisions to the Pharmacokinetics-Protein Binding and the Precautions-Drug Interactions sections based upon information derived from *in vivo* studies to examine the effects of nefazodone on the pharmacokinetics of warfarin, fluoxetine, phenytoin, desipramine, lithium, carbamazepine, and theophylline.

We have completed the review of this supplemental application, including the submitted draft labeling, and have concluded that, with the exception of the carbamazepine interaction, this supplemental application is approvable, pending your agreement with additional labeling changes regarding the carbamazepine interaction.

Among the drug interaction data submitted in your August 8, 1996 submission, the interaction of greatest concern to us is the very pronounced increase in the clearance of nefazodone and hydroxy-nefazodone associated with the concomitant administration of even a relatively low dose of carbamazepine, i.e., 200 mg bid. The AUCs for parent and metabolite were reduced by almost 95%, effectively moving the patients to an untreated state regarding antidepressant drug.

Since a proportion of patients would be expected to have depressive relapses under such circumstances, and we consider that a serious clinical event, it is our view that the concomitant use of nefazodone and carbamazepine cannot be recommended. Consequently, we are asking that you include a Contraindications statement, a Warnings statement, and a revised Drug Interactions statement for this interaction.

We propose the following language for these revised sections:

CONTRAINDICATIONS

_____]

WARNINGS

[The following language should be added as the last paragraph in this section.]

Interaction with Carbamazepine

The coadministration of carbamazepine 200 mg bid with nefazodone 200 mg bid, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxy-nefazodone, likely resulting in insufficient plasma nefazodone and hydroxy-nefazodone concentrations for achieving an antidepressant effect for Serzone. Consequently, it is recommended that Serzone not be used in combination with carbamazepine (see Contraindications and Precautions sections).

PRECAUTIONS

Drug Interactions

[The following language should replace the last two sentences of your proposed language for the carbamazepine statement.]

Due to the potential for co-administration of carbamazepine to result in insufficient plasma nefazodone and hydroxy-nefazodone concentrations for achieving an antidepressant effect for Serzone, it is recommended that Serzone not be used in combination with carbamazepine (see Contraindications and Warnings sections).

The final printed labeling (FPL) must be identical to the draft labeling submitted on August 8, 1996 except for the additions and revisions noted above.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved supplemental NDA 20-152/S-006. Approval of this submission by FDA is not required before the labeling is used.

If you have any questions concerning this supplemental NDA, please contact Mr. Paul David, Project Manager, at (301) 594-5530.

/s/

Paul Leber, M.D.
Director
Division of Neuropharmacological
Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

ORIG NDA 20-152/S-006

HFD-92/DDM-DIAB

HFD-120/DIV FILE

HFD-120/PLeber/TLaughren/EHearst

HFD-120/PDavid/JWare

HFD-860/RBaweja

HFD-613

HFD-735/DPE

HFD-40/DDMAC (with draft labeling)

District Office

rd:03/11/98pd

rev:03/17/98tl

ft:03/17/98pd

Doc #SERZONE/S-006AP.LTR

SUPPLEMENTAL APPLICATION APPROVABLE

5-18-98

3/1/98

+ 5-17-98

3/17/98

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-152/S-006

FINAL PRINTED LABEL

SERZONE[®]


(nefazodone hydrochloride) Tablets

Rx only

DESCRIPTION

SERZONE[®] (nefazodone hydrochloride) is an antidepressant for oral administration with a chemical structure unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI).

Nefazodone hydrochloride is a synthetically derived phenylpiperazine antidepressant. The chemical name for nefazodone hydrochloride is 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one monohydrochloride. The molecular formula is $C_{25}H_{32}ClN_5O_2 \cdot HCl$, which corresponds to a molecular weight of 506.5. The structural formula is:



Nefazodone hydrochloride is a nonhygroscopic, white crystalline solid. It is freely soluble in chloroform, soluble in propylene glycol, and slightly soluble in polyethylene glycol and water.

SERZONE is supplied as hexagonal tablets containing 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg of nefazodone hydrochloride and the following inactive ingredients: microcrystalline cellulose, povidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and iron oxides (red and/or yellow) as colorants.

CLINICAL PHARMACOLOGY

Pharmacodynamics

The mechanism of action of nefazodone, as with other antidepressants, is unknown.

Preclinical studies have shown that nefazodone inhibits neuronal uptake of serotonin and norepinephrine.

Nefazodone occupies central 5-HT₂ receptors at nanomolar concentrations, and acts as an antagonist at this receptor. Nefazodone was shown to antagonize alpha₁-adrenergic receptors, a property which may be associated with postural hypotension. *In vitro* binding studies showed that nefazodone had no significant affinity for the following receptors: alpha₂ and beta adrenergic, 5-HT_{1A}, cholinergic, dopaminergic, or benzodiazepine.

Pharmacokinetics

Nefazodone hydrochloride is rapidly and completely absorbed but is subject to extensive metabolism, so that its absolute bioavailability is low, about 20%, and variable. Peak plasma concentrations occur at about one hour and the half-life of nefazodone is 2–4 hours.

Both nefazodone and its pharmacologically similar metabolite, hydroxynefazodone, exhibit nonlinear kinetics for both dose and time, with AUC and C_{max} increasing more than proportionally with dose increases and more than expected upon multiple dosing over time, compared to single dosing. For example, in a multiple-dose study involving BID dosing with 50, 100, and 200 mg, the AUC for nefazodone and hydroxynefazodone increased by about 4-fold with an increase in dose from 200 to 400 mg per day; C_{max} increased by about 3-fold with the same dose increase. In a multiple-dose study involving BID dosing with 25, 50, 100, and 150 mg, the accumulation ratios for nefazodone and hydroxynefazodone AUC, after 5 days of BID dosing relative to the first dose, ranged from approximately 3 to 4 at the lower doses (50–100 mg/day) and from 5 to 7 at the higher doses (200–300 mg/day); there were also approximately 2- to 4-fold increases in C_{max} after 5 days of BID dosing relative to the first dose, suggesting extensive and greater than predicted accumulation of nefazodone and its hydroxy metabolite with multiple dosing. Steady-state plasma nefazodone and metabolite concentrations are attained within 4 to 5 days of initiation of BID dosing or upon dose increase or decrease.

Nefazodone is extensively metabolized after oral administration by *n*-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine. Attempts to characterize three metabolites identified in plasma, hydroxynefazodone (HO-NEF), meta-chlorophenylpiperazine (mCPP), and a triazole-dione metabolite, have been carried out. The AUC (expressed as a multiple of the AUC for nefazodone dosed at 100 mg BID) and elimination half-lives for these three metabolites were as follows:

AUC Multiples and $T_{1/2}$ for Three Metabolites of Nefazodone (100 mg BID)		
Metabolite	AUC Multiple	$T_{1/2}$
HO-NEF	0.4	1.5–4 h
mCPP	0.07	4–8 h
Triazole-dione	4.0	18 h

HO-NEF possesses a pharmacological profile qualitatively and quantitatively similar to that of nefazodone. mCPP has some similarities to nefazodone, but also has agonist activity at some serotonergic receptor subtypes. The pharmacological profile of the triazole-dione metabolite has not yet been well characterized. In addition to the above compounds, several other metabolites were present in plasma but have not been tested for pharmacological activity.

After oral administration of radiolabeled nefazodone, the mean half-life of total label ranged between 11 and 24 hours. Approximately 55% of the administered radioactivity was detected in urine and about 20–30% in feces.

Distribution—Nefazodone is widely distributed in body tissues, including the central nervous system (CNS). In humans the volume of distribution of nefazodone ranges from 0.22 to 0.87 L/kg.

Protein Binding—At concentrations of 25–2500 ng/mL nefazodone is extensively (>99%) bound to human plasma proteins *in vitro*. The administration of 200 mg BID of nefazodone for 1 week did not increase the fraction of unbound warfarin in subjects whose prothrombin times had been prolonged by warfarin therapy to 120–150% of the laboratory control (see PRECAUTIONS section, Drug Interactions subsection). While nefazodone did not alter the *in vitro* protein binding of chlorpromazine, desipramine, diazepam, diphenhydantoin, lidocaine, prazosin, propranolol, or verapamil, it is unknown whether displacement of either nefazodone or these drugs occurs *in vivo*. There was a 5% decrease in the protein binding of haloperidol; this is probably of no clinical significance.

Effect of Food—Food delays the absorption of nefazodone and decreases the bioavailability of nefazodone by approximately 20%.

Renal Disease—In studies involving 29 renally impaired patients, renal impairment (creatinine clearances ranging from 7 to 60 mL/min/1.73m²) had no effect on steady-state nefazodone plasma concentrations.

Liver Disease—In a multiple-dose study of patients with liver cirrhosis, the AUC values for nefazodone and HO-NEF at steady state were approximately 25% greater than those observed in normal volunteers.

Age/Gender Effects—After single doses of 300 mg to younger (18–45 years) and older patients (>65 years), C_{max} and AUC for nefazodone and hydroxynefazodone were up to twice as high in the older patients. With multiple doses, however, differences were much smaller, 10–20%. A similar result was seen for gender, with a higher C_{max} and AUC in women after single doses but no difference after multiple doses.

Treatment with SERZONE should be initiated at half the usual dose in elderly patients, especially women (see DOSAGE AND ADMINISTRATION section), but the therapeutic dose range is similar in younger and older patients.

Clinical Efficacy Trial Results

Studies in Outpatients with Depression

During its premarketing development, the efficacy of SERZONE was evaluated at doses within the therapeutic range in five well-controlled, short-term (6–8 weeks) clinical investigations. These trials enrolled outpatients meeting DSM-III or DSM-III-R criteria for major depression. Among these trials, two demonstrated the effectiveness of SERZONE, and two provided additional support for that conclusion.

One trial was a 6-week dose-titration study comparing SERZONE in two dose ranges (up to 300 mg/day and up to 600 mg/day [mean modal dose for this group was about 400 mg/day], on a BID schedule) and placebo. The second trial was an 8-week dose-titration study comparing SERZONE (up to 600 mg/day; mean modal dose was 375 mg/day), imipramine (up to 300 mg/day), and placebo, all on a BID schedule. Both studies demonstrated SERZONE, at doses titrated between 300 mg to 600 mg/day (therapeutic dose range), to be superior to placebo on at least three of the following four measures: 17-item Hamilton Depression Rating Scale or HDRS (total score), Hamilton Depressed Mood item, Clinical Global Impressions (CGI) Severity score, and CGI improvement score. Significant differences were also found for certain factors of the HDRS (e.g., anxiety factor, sleep disturbance factor, and retardation factor). In the two supportive studies, SERZONE was titrated up to 500 or 600 mg/day (mean modal doses of 462 mg/day and 363 mg/day). In the fifth study, the differentiation in response rates between SERZONE and placebo was not statistically significant. Three additional trials were conducted using subtherapeutic doses of SERZONE.

Overall, approximately two thirds of patients in these trials were women, and an analysis of the effects of gender on outcome did not suggest any differential responsiveness on the basis of sex. There were too few elderly patients in these trials to reveal possible age-related differences in response.

Since its initial marketing as an antidepressant drug product, additional clinical investigations of SERZONE have been conducted. These studies explored SERZONE's use under conditions not evaluated fully at the time initial marketing approval was granted.

Studies in "Inpatients"

Two studies were conducted to evaluate SERZONE's effectiveness in hospitalized depressed patients. These were 6-week, dose-titration trials comparing SERZONE (up to 600 mg/day) and placebo, on a BID schedule. In one study, SERZONE was superior to placebo. In this study, the mean modal dose of SERZONE was 503 mg/day, and 85% of these inpatients were melancholic; at baseline, patients were distributed at the higher end of the 7-point CGI Severity scale, as follows: 4=moderately ill (17%); 5=markedly ill (48%); 6=severely ill (32%). In the other study, the differentiation in response rates between SERZONE and placebo was not statistically significant. This result may be explained by the "high" rate of spontaneous improvement among the patients randomized to placebo.

Studies of "Relapse Prevention in Patients Recently Recovered (Clinically) from Depression"

Two studies were conducted to assess SERZONE's capacity to maintain a clinical remission in acutely depressed patients who were judged to have responded adequately (HDRS total score ≤ 10) after a 16-week period of open treatment with SERZONE (titration up to 600 mg/day). In one study, SERZONE was superior to placebo. In this study, patients (n=131) were randomized to continuation on SERZONE or placebo for an additional 36 weeks (1 year total). This study demonstrated a significantly lower relapse rate (HDRS total score ≥ 18) for patients taking SERZONE compared to those on placebo. The second study was of appropriate design and power, but the sample of patients admitted for evaluation did not suffer relapses at a high enough incidence to provide a meaningful test of SERZONE's efficacy for this use.

Comparisons of Clinical Trial Results

Highly variable results have been seen in the clinical development of all antidepressant drugs. Furthermore, in those circumstances when the drugs have not been studied in the same controlled clinical trial(s), comparisons among the findings of studies evaluating the effectiveness of different antidepressant drug products are inherently unreliable. Because conditions of testing (e.g., patient samples, investigators, doses of the treatments administered and compared, outcome measures, etc.) vary among trials, it is virtually impossible to distinguish a difference in drug effect from a difference due to one or more of the confounding factors just enumerated.

INDICATIONS AND USAGE

SERZONE (nefazodone hydrochloride) is indicated for the treatment of depression.

The efficacy of SERZONE in the treatment of depression was established in 6–8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depressive disorder (see CLINICAL PHARMACOLOGY section).

A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). It must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.

The efficacy of SERZONE in reducing relapse in patients with major depression who were judged to have had a satisfactory clinical response to 16 weeks of open-label SERZONE treatment for an acute depressive episode has been demonstrated in a randomized placebo-controlled trial (see CLINICAL PHARMACOLOGY section). Although remitted patients were followed for as long as 36 weeks in the study cited (i.e., 52 weeks total), the physician who elects to use SERZONE for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.

CONTRAINDICATIONS

Coadministration of terfenadine, astemizole, cisapride, pimozide, or carbamazepine with SERZONE (nefazodone hydrochloride) is contraindicated (see WARNINGS and PRECAUTIONS sections).

SERZONE is contraindicated in patients with known hypersensitivity to nefazodone or other phenylpiperazine antidepressants.

The coadministration of triazolam and nefazodone causes a significant increase in the plasma level of triazolam (see WARNINGS and PRECAUTIONS sections), and a 75% reduction in the initial triazolam dosage is recommended if the two drugs are to be given together. Because not all commercially available dosage forms of triazolam permit a sufficient dosage reduction, the coadministration of triazolam and SERZONE should be avoided for most patients, including the elderly.

WARNINGS

Potential for Interaction with Monoamine Oxidase Inhibitors

In patients receiving antidepressants with pharmacological properties similar to nefazodone in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions. For a selective serotonin reuptake inhibitor (SSRI), these reactions have included hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued that drug and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Severe hyperthermia and seizures, sometimes fatal, have been reported in association with the combined use of tricyclic antidepressants and MAOIs. These reactions have also been reported in patients who have recently discontinued these drugs and have been started on an MAOI.

Although the effects of combined use of nefazodone and MAOI have not been evaluated in humans or animals, because nefazodone is an inhibitor of both serotonin and norepinephrine reuptake, it is recommended that nefazodone not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. At least 1 week should be allowed after stopping nefazodone before starting an MAOI.

Interaction with Triazolobenzodiazepines

Interaction studies of nefazodone with two triazolobenzodiazepines, i.e., triazolam and alprazolam, metabolized by cytochrome P450 3A4, have revealed substantial and clinically important increases in plasma concentrations of these compounds when administered concomitantly with nefazodone.

Triazolam

When a single oral 0.25-mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. If triazolam is coadministered with SERZONE, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with SERZONE should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with SERZONE may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS sections).

Alprazolam

When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with SERZONE, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for SERZONE.

Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions

Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsades de pointes type. Nefazodone has been shown *in vitro* to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine, astemizole, cisapride, or pimozide (see CONTRAINDICATIONS and PRECAUTIONS sections).

Interaction with Carbamazepine

The coadministration of carbamazepine 200 mg BID with nefazodone 200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving an antidepressant effect for SERZONE. Consequently, it is recommended that SERZONE not be used in combination with carbamazepine (see CONTRAINDICATIONS and PRECAUTIONS sections).

PRECAUTIONS

General

Postural Hypotension

A pooled analysis of the vital signs monitored during placebo-controlled premarketing studies revealed that 5.1% of nefazodone patients compared to 2.5% of placebo patients ($p < 0.01$) met criteria for a potentially important decrease in blood pressure at some time during treatment (systolic blood pressure ≤ 90 mmHg and a change from baseline of ≥ 20 mmHg). While there was no difference in the proportion of nefazodone and placebo patients having adverse events characterized as 'syncope' (nefazodone, 0.2%; placebo, 0.3%), the rates for adverse events characterized as 'postural hypotension' were as follows: nefazodone (2.8%), tricyclic antidepressants (10.9%), SSRI (1.1%), and placebo (0.8%). Thus, the prescriber should be aware that there is some risk of postural hypotension in association with nefazodone use. SERZONE should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication).

Activation of Mania/Hypomania

During premarketing testing, hypomania or mania occurred in 0.3% of nefazodone-treated unipolar patients, compared to 0.3% of tricyclic- and 0.4% of placebo-treated patients. In patients classified as bipolar the rate of manic episodes was 1.6% for nefazodone, 5.1% for the combined tricyclic-treated groups, and 0% for placebo-treated patients. Activation of mania/hypomania is a known risk in a small proportion of patients with major affective disorder treated with other marketed antidepressants. As with all antidepressants, SERZONE (nefazodone hydrochloride) should be used cautiously in patients with a history of mania.

Suicide

The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Close supervision of high-risk patients should accompany initial drug therapy. Prescriptions for SERZONE should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Seizures

During premarketing testing, a recurrence of a petit mal seizure was observed in a patient receiving nefazodone who had a history of such seizures. In addition, one nonstudy participant reportedly experienced a convulsion (type not documented) following a multiple-drug overdose (see OVERDOSAGE section). Rare occurrences of convulsions (including grand mal seizures) following nefazodone administration have been reported since market introduction. A causal relationship to nefazodone has not been established (see ADVERSE REACTIONS section).

Priapism

While priapism did not occur during premarketing experience with nefazodone, rare reports of priapism have been received since market introduction. A causal relationship to nefazodone has not been established (see ADVERSE REACTIONS section). If patients present with prolonged or inappropriate erections, they should discontinue therapy immediately and consult their physicians. If the condition persists for more than 24 hours, a urologist should be consulted to determine appropriate management.

Use in Patients with Concomitant Illness

SERZONE has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies during the product's premarketing testing. Evaluation of electrocardiograms of 1153 patients who received nefazodone in 6- to 8-week, double-blind, placebo-controlled trials did not indicate that nefazodone is associated with the development of clinically important ECG abnormalities. However, sinus bradycardia, defined as heart rate ≤ 50 bpm and a decrease of at least 15 bpm from baseline, was observed in 1.5% of nefazodone-treated patients compared to 0.4% of placebo-treated patients ($p \leq 0.05$). Because patients with a recent history of myocardial infarction or unstable heart disease were excluded from clinical trials, such patients should be treated with caution.

In patients with cirrhosis of the liver, the AUC values of nefazodone and HO-NEF were increased by approximately 25%.

Information for Patients

Physicians are advised to discuss the following issues with patients for whom they prescribe SERZONE:

Time to Response/Continuation

As with all antidepressants, several weeks on treatment may be required to obtain the full antidepressant effect. Once improvement is noted, it is important for patients to continue drug treatment as directed by their physician.

Interference With Cognitive and Motor Performance

Since any psychoactive drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that SERZONE therapy does not adversely affect their ability to engage in such activities.

Pregnancy

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.

Nursing

Patients should be advised to notify their physician if they are breast-feeding an infant (see PRECAUTIONS section, Nursing Mothers subsection).

Concomitant Medication

Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions. Significant caution is indicated if SERZONE is to be used in combination with XANAX[®], concomitant use with HALCION[®] should be avoided for most patients including the elderly, and concomitant use with SELDANE[®], HISMANAL[®], PROPULSID[®], ORAP[®], or TEGRETOL[®] is contraindicated (see CONTRAINDICATIONS and WARNINGS sections).

Alcohol

Patients should be advised to avoid alcohol while taking SERZONE.

Allergic Reactions

Patients should be advised to notify their physician if they develop a rash, hives, or a related allergic phenomenon.

Laboratory Tests

There are no specific laboratory tests recommended.

Drug Interactions

Drugs Highly Bound to Plasma Protein

Because nefazodone is highly bound to plasma protein (see CLINICAL PHARMACOLOGY section, Pharmacokinetics subsection), administration of SERZONE to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse events. Conversely, adverse effects could result from displacement of nefazodone by other highly bound drugs.

Warfarin—There were no effects on the prothrombin or bleeding times or upon the pharmacokinetics of R-warfarin when nefazodone (200 mg BID) was administered for 1 week to subjects who had been pretreated for 2 weeks with warfarin. Although the coadministration of nefazodone did decrease the subjects' exposure to S-warfarin by 12%, the lack of effects on the prothrombin and bleeding times indicates this modest change is not clinically significant. Although these results suggest no adjustments in warfarin dosage are required when nefazodone is administered to patients stabilized on warfarin, such patients should be monitored as required by standard medical practices.

CNS-Active Drugs

Monoamine Oxidase Inhibitors—See WARNINGS section.

Haloperidol—When a single oral 5-mg dose of haloperidol was coadministered with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance decreased by 35% with no significant increase in peak haloperidol plasma concentrations or time of peak. This change is of unknown clinical significance. Pharmacodynamic effects of haloperidol were generally not altered significantly. There were no changes in the pharmacokinetic parameters for nefazodone. Dosage adjustment of haloperidol may be necessary when coadministered with nefazodone.

Lorazepam—When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.

Triazolam/Alprazolam—See CONTRAINDICATIONS and WARNINGS sections.

Alcohol—Although nefazodone did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of SERZONE and alcohol in depressed patients is not advised.

Bupropion—In a study of steady-state pharmacokinetics in healthy volunteers, coadministration of bupropion (2.5 or 5 mg BID) with nefazodone (250 mg BID) resulted in marked increases in plasma bupropion concentrations (increases up to 20-fold in C_{max} and up to 50-fold in AUC) and statistically significant decreases (about 50%) in plasma concentrations of the bupropion metabolite 1-pyrimidinylpiperazine. With 5-mg BID doses of bupropion, slight increases in AUC were observed for nefazodone (23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%). The side effect profile for subjects receiving bupropion 2.5 mg BID and nefazodone 250 mg BID was similar to that for subjects receiving either drug alone. Subjects receiving bupropion 5 mg BID and nefazodone 250 mg BID experienced side effects such as lightheadedness, asthenia, dizziness, and somnolence. If the two drugs are to be used in combination, a low dose of bupropion (e.g., 2.5 mg BID) is recommended. Subsequent dose adjustment of either drug should be based on clinical assessment.

Pimozide—See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Pharmacokinetics of Nefazodone in 'Poor Metabolizers' and Potential Interaction with Drugs that Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes.

Fluoxetine—When fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered at steady state there were no changes in the pharmacokinetic parameters for fluoxetine or its metabolite, norfluoxetine. Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3- to 6-fold and 1.3-fold, respectively. When a 200-mg dose of nefazodone was administered to subjects who had been receiving fluoxetine for 1 week, there was an increased incidence of transient adverse events such as headache, lightheadedness, nausea, or paresthesia, possibly due to the elevated mCPP levels. Patients who are switched from fluoxetine to nefazodone without an adequate washout period may experience similar transient adverse events. The possibility of this happening can be minimized by allowing a washout period before initiating nefazodone therapy and by reducing the initial dose of nefazodone. Because of the long half-life of fluoxetine and its metabolites, this washout period may range from one to several weeks depending on the dose of fluoxetine and other individual patient variables.

Phenytoin—Pretreatment for 7 days with 200 mg BID of nefazodone had no effect on the pharmacokinetics of a single 300-mg oral dose of phenytoin. However, due to the nonlinear pharmacokinetics of phenytoin, the failure to observe a significant effect on the single-dose pharmacokinetics of phenytoin does not preclude the possibility of a clinically significant interaction with nefazodone when phenytoin is dosed chronically. However, no change in the initial dosage of phenytoin is considered necessary and any subsequent adjustment of phenytoin dosage should be guided by usual clinical practices.

Desipramine—When nefazodone (150 mg BID) and desipramine (75 mg QD) were administered together there were no changes in the pharmacokinetics of desipramine or its metabolite, 2-hydroxy desipramine. There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and C_{max} of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. No changes in doses of either nefazodone or desipramine are necessary when the two drugs are given concomitantly. Subsequent dose adjustments should be made on the basis of clinical response.

Lithium—In 13 healthy subjects the coadministration of nefazodone (200 mg BID) with lithium (500 mg BID) for 5 days (steady-state conditions) was found to be well tolerated. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance. Therefore, no dosage adjustment of either lithium or nefazodone is required when they are coadministered.

Carbamazepine—The coadministration of nefazodone (200 mg BID) for 5 days to 12 healthy subjects on carbamazepine who had achieved steady state (200 mg BID) was found to be well tolerated. Steady-state conditions for carbamazepine, nefazodone, and several of their metabolites were achieved by day 5 of coadministration. With coadministration of the two drugs there were significant increases in the steady-state C_{max} and AUC of carbamazepine (23% and 23%, respectively), while the steady-state C_{max} and the AUC of the carbamazepine metabolite, 10,11 epoxycarbamazepine, decreased by 21% and 20%, respectively. The coadministration of the two drugs significantly reduced the steady-state C_{max} and AUC of nefazodone by 86% and 93%, respectively. Similar reductions in the C_{max} and AUC of HO-NEF were also observed (85% and 94%), while the reductions in C_{max} and AUC of mCPP and triazole-dione were more modest (13% and 44% for the former and 28% and 57% for the latter). Due to the potential for coadministration of carbamazepine to result in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving an antidepressant effect for SERZONE, it is recommended that SERZONE not be used in combination with carbamazepine (see CONTRAINDICATIONS and WARNINGS sections).

General Anesthetics—Little is known about the potential for interaction between nefazodone and general anesthetics; therefore, prior to elective surgery, SERZONE should be discontinued for as long as clinically feasible.

Other CNS-Active Drugs—The use of nefazodone in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised if concomitant administration of SERZONE (nefazodone hydrochloride) and such drugs is required.

Cimetidine

When nefazodone (200 mg BID) and cimetidine (300 mg QID) were coadministered for one week, no change in the steady-state pharmacokinetics of either nefazodone or cimetidine was observed compared to each dosed alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.

Theophylline

When nefazodone (200 mg BID) was given to patients being treated with theophylline (600-1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV₁ measurements taken when theophylline and nefazodone were

coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered.

Cardiovascular-Active Drugs

Digoxin—When nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered for 9 days to healthy male volunteers (n=18) who were phenotyped as CYP2D6 extensive metabolizers, C_{max}, C_{min}, and AUC of digoxin were increased by 29%, 27%, and 15%, respectively. Digoxin had no effects on the pharmacokinetics of nefazodone and its active metabolites. Because of the narrow therapeutic index of digoxin, caution should be exercised when nefazodone and digoxin are coadministered; plasma level monitoring for digoxin is recommended.

Propranolol—The coadministration of nefazodone (200 mg BID) and propranolol (40 mg BID) for 5.5 days to healthy male volunteers (n=18), including 3 poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14% reductions in C_{max} and AUC of propranolol, respectively, and a 14% reduction in C_{max} for the metabolite, 4-hydroxypropranolol. The kinetics of nefazodone, hydroxynefazodone, and triazole-dione were not affected by coadministration of propranolol. However, C_{max}, C_{min}, and AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and 28%, respectively. No change in initial dose of either drug is necessary and dose adjustments should be made on the basis of clinical response.

HMG-CoA Reductase Inhibitors—When single 40-mg doses of simvastatin or atorvastatin, both substrates of CYP3A4, were given to healthy adult volunteers who had received SERZONE 200 mg BID for 6 days, approximately 20-fold increases in plasma concentrations of simvastatin and simvastatin acid and 3- to 4-fold increases in plasma concentrations of atorvastatin and atorvastatin lactone were seen. These effects appear to be due to the inhibition of CYP3A4 by SERZONE because, in the same study, SERZONE had no significant effect on the plasma concentrations of pravastatin, which is not metabolized by CYP3A4 to a clinically significant extent.

There have been rare reports of rhabdomyolysis involving patients receiving the combination of SERZONE and either simvastatin or lovastatin, also a substrate of CYP3A4 (see **ADVERSE REACTIONS: Postintroduction Clinical Experience** section). Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) and in particular, for certain drugs in this class, when given in combination with inhibitors of the CYP3A4 isozyme.

Caution should be used if SERZONE is administered in combination with HMG-CoA reductase inhibitors that are metabolized by CYP3A4, such as simvastatin, atorvastatin, and lovastatin, and dosage adjustments of these HMG-CoA reductase inhibitors are recommended. Since metabolic interactions are unlikely between SERZONE and HMG-CoA reductase inhibitors that undergo little or no metabolism by the CYP3A4 isozyme, such as pravastatin or fluvastatin, dosage adjustments should not be necessary.

Immunosuppressive Agents

There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with SERZONE. Both cyclosporine and tacrolimus are substrates of CYP3A4, and nefazodone is known to inhibit this enzyme. If either cyclosporine or tacrolimus is administered with SERZONE, blood concentrations of the immunosuppressive agent should be monitored and dosage adjusted accordingly.

Pharmacokinetics of Nefazodone in "Poor Metabolizers" and Potential Interaction with Drugs that Inhibit and/or Are Metabolized by Cytochrome P450 Isozymes

CYP3A4 Isozyme—Nefazodone has been shown *in vitro* to be an inhibitor of CYP3A4. This is consistent with the interactions observed between nefazodone and triazolam, alprazolam, buspirone, atorvastatin, and simvastatin, drugs metabolized by this isozyme. Consequently, caution is indicated in the combined use of nefazodone with any drugs known to be metabolized by CYP3A4. In particular, the combined use of nefazodone with triazolam should be avoided for most patients, including the elderly. The combined use of nefazodone with terfenadine, astemizole, cisapride, or pimozide is contraindicated (see **CONTRAINDICATIONS** and **WARNINGS** sections).

CYP2D6 Isozyme—A subset (3% to 10%) of the population has reduced activity of the drug-metabolizing enzyme CYP2D6. Such individuals are referred to commonly as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. The pharmacokinetics of nefazodone and its major metabolites are not altered in these "poor metabolizers." Plasma concentrations of one minor metabolite (mCPP) are increased in this population; the adjustment of SERZONE dosage is not required when administered to "poor metabolizers." Nefazodone and its metabolites have been shown *in vitro* to be extremely weak inhibitors of CYP2D6. Thus, it is not likely that nefazodone will decrease the metabolic clearance of drugs metabolized by this isozyme.

CYP1A2 Isozyme—Nefazodone and its metabolites have been shown *in vitro* not to inhibit CYP1A2. Thus, metabolic interactions between nefazodone and drugs metabolized by this isozyme are unlikely.

Electroconvulsive Therapy (ECT)

There are no clinical studies of the combined use of ECT and nefazodone.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

There is no evidence of carcinogenicity with nefazodone. The dietary administration of nefazodone to rats and mice for 2 years at daily doses of up to 200 mg/kg and 800 mg/kg, respectively, which are approximately 3 and 6 times, respectively, the maximum human daily dose on a mg/m² basis, produced no increase in tumors.

Mutagenesis

Nefazodone has been shown to have no genotoxic effects based on the following assays: bacterial mutation assays, a DNA repair assay in cultured rat hepatocytes, a mammalian mutation assay in Chinese hamster ovary cells, an *in vivo* cytogenetics assay in rat bone marrow cells, and a rat dominant lethal study.

Impairment of Fertility

A fertility study in rats showed a slight decrease in fertility at 200 mg/kg/day (approximately three times the maximum human daily dose on a mg/m² basis) but not at 100 mg/kg/day (approximately 1.5 times the maximum human daily dose on a mg/m² basis).

Pregnancy

Teratogenic Effects—Pregnancy Category C

Reproduction studies have been performed in pregnant rabbits and rats at daily doses up to 200 and 300 mg/kg, respectively (approximately 6 and 5 times, respectively, the maximum human daily dose on a mg/m² basis). No malformations were observed in the offspring as a result of nefazodone treatment. However, increased early pup mortality was seen in rats at a dose approximately five times the maximum human dose, and decreased pup weights were seen at this and lower doses, when dosing began during pregnancy and continued until weaning. The cause of these deaths is not known. The no-effect dose for rat pup mortality was 1.3 times the human dose on a mg/m² basis. There are no adequate and well-controlled studies in pregnant women. Nefazodone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery

The effect of SERZONE (nefazodone hydrochloride) on labor and delivery in humans is unknown.

Nursing Mothers

It is not known whether SERZONE or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SERZONE is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in individuals below 18 years of age have not been established.

Geriatric Use

Of the approximately 7000 patients in clinical studies who received SERZONE for the treatment of depression, 18% were 65 years and older, while 5% were 75 years and older. Based on monitoring of adverse events, vital signs, electrocardiograms, and results of laboratory tests, no overall differences in safety between elderly and younger patients were observed in clinical studies. Efficacy in the elderly has not been demonstrated in placebo-controlled trials. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Due to the increased systemic exposure to nefazodone seen in single-dose studies in elderly patients (see **CLINICAL PHARMACOLOGY** section, **Pharmacokinetics** subsection), treatment should be initiated at half

the usual dose, but titration upward should take place over the same range as in younger patients (see **DOSE AND ADMINISTRATION** section). The usual precautions should be observed in elderly patients who have concomitant medical illnesses or who are receiving concomitant drugs.

ADVERSE REACTIONS

Associated with Discontinuation of Treatment

Approximately 16% of the 3496 patients who received SERZONE (nefazodone hydrochloride) in worldwide premarketing clinical trials discontinued treatment due to an adverse experience. The more common (≥1%) events in clinical trials associated with discontinuation and considered to be drug related (i.e., those events associated with dropout at a rate approximately twice or greater for SERZONE-compared to placebo) included: nausea (3.5%), dizziness (1.9%), insomnia (1.5%), asthenia (1.3%), and agitation (1.2%).

Incidence in Controlled Trials

Commonly Observed Adverse Events in Controlled Clinical Trials

The most commonly observed adverse events associated with the use of SERZONE (incidence of 5% or greater) and not seen at an equivalent incidence among placebo-treated patients (i.e., significantly higher incidence for SERZONE compared to placebo, p≤0.05), derived from the table below, were: somnolence, dry mouth, nausea, dizziness, constipation, asthenia, lightheadedness, blurred vision, confusion, and abnormal vision.

Adverse Events Occurring at an Incidence of 1% or More Among SERZONE-Treated Patients

The table that follows enumerates adverse events that occurred at an incidence of 1% or more, and were more frequent than in the placebo group, among SERZONE-treated patients who participated in short-term (6- to 8-week) placebo-controlled trials in which patients were dosed with SERZONE (nefazodone hydrochloride) to ranges of 300 to 600 mg/day. This table shows the percentage of patients in each group who had at least one episode of an event at some time during their treatment. Reported adverse events were classified using standard COSTART-based Dictionary terminology.

The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side-effect incidence rate in the population studied.

Treatment-Emergent Adverse Experience Incidence in 6- to 8-Week Placebo-Controlled Clinical Trials¹, SERZONE 300 to 600 mg/day Dose Range

Body System	Preferred Term	Percent of Patients		
		SERZONE (n=393)	Placebo (n=394)	
Body as a Whole	Headache	36	33	
	Asthenia	11	5	
	Infection	8	6	
	Flu syndrome	3	2	
	Chills	2	1	
	Fever	2	1	
	Neck rigidity	1	0	
	Cardiovascular	Postural hypotension	4	1
		Hypotension	2	1
	Dermatological	Pruritus	2	1
Rash		2	1	
Gastrointestinal	Dry mouth	25	13	
	Nausea	22	12	
	Constipation	14	8	
	Dyspepsia	9	7	
	Diarrhea	8	7	
	Increased appetite	5	3	
	Nausea & vomiting	2	1	
	Metabolic	Peripheral edema	3	2
		Thirst	1	<1
	Musculoskeletal	Arthralgia	1	<1
Nervous		Somnolence	25	14
	Dizziness	17	5	
	Insomnia	11	9	
	Lightheadedness	10	3	
	Confusion	7	2	
	Memory impairment	4	2	
	Paresthesia	4	2	
	Vasodilatation ²	4	2	
	Abnormal dreams	3	2	
	Concentration decreased	3	1	
Respiratory	Ataxia	2	0	
	Incoordination	2	1	
	Psychomotor retardation	2	1	
	Tremor	2	1	
	Hypertonia	1	0	
	Libido decreased	1	<1	
	Pharyngitis	6	5	
	Cough increased	3	1	
	Special Senses	Blurred vision	9	3
		Abnormal vision ³	7	1
Tinnitus		2	1	
Urogenital	Taste perversion	2	1	
	Visual field defect	2	0	
	Urinary frequency	2	1	
	Urinary tract infection	2	1	
	Urinary retention	2	1	
	Vaginitis ⁴	2	1	
	Breast pain ⁴	1	<1	

¹ Events reported by at least 1% of patients treated with SERZONE and more frequent than the placebo group are included; incidence is rounded to the nearest 1% (<1% indicates an incidence less than 0.5%). Events for which the SERZONE incidence was equal to or less than placebo are not listed in the table, but included the following: abdominal pain, pain, back pain, accidental injury, chest pain, neck pain, palpitation, migraine, sweating, flatulence, vomiting, anorexia, tooth disorder, weight gain, edema, myalgia, cramp, agitation, anxiety, depression, hypesthesia, CNS stimulation, dysphoria, emotional lability, sinusitis, rhinitis, dysmenorrhea⁴, dysuria.

² Vasodilatation—flushing, feeling warm.

³ Abnormal vision—scotoma, visual trails.

⁴ Incidence adjusted for gender.

Dose Dependency of Adverse Events

The table that follows enumerates adverse events that were more frequent in the SERZONE (nefazodone hydrochloride) dose range of 300 to 600 mg/day than in the SERZONE dose range of up to 300 mg/day. This

table shows only those adverse events for which there was a statistically significant difference ($p \leq 0.05$) in incidence between the SERZONE dose ranges as well as a difference between the high dose range and placebo.

Dose Dependency of Adverse Events in Placebo-Controlled Trials¹

Body System	Preferred Term	Percent of Patients		
		SERZONE 300–600 mg/day (n = 209)	SERZONE ≤300 mg/day (n = 211)	Placebo (n = 212)
Gastrointestinal	Nausea	23	14	12
	Constipation	17	10	9
	Somnolence	28	16	13
Nervous	Dizziness	22	11	4
	Confusion	8	2	1
Special Senses	Abnormal vision	10	0	2
	Blurred vision	9	3	2
	Tinnitus	3	0	1

¹ Events for which there was a statistically significant difference ($p \leq 0.05$) between the nefazodone dose groups.

Vital Sign Changes

(See PRECAUTIONS section, Postural Hypotension subsection.)

Weight Changes

In a pooled analysis of placebo-controlled premarketing studies, there were no differences between nefazodone and placebo groups in the proportions of patients meeting criteria for potentially important increases or decreases in body weight (a change of $\geq 7\%$).

Laboratory Changes

Of the serum chemistry, serum hematology, and urinalysis parameters monitored during placebo-controlled premarketing studies with nefazodone, a pooled analysis revealed a statistical trend between nefazodone and placebo for hematocrit, i.e., 2.8% of nefazodone patients met criteria for a potentially important decrease in hematocrit ($\leq 37\%$ male or $\leq 32\%$ female) compared to 1.5% of placebo patients ($0.05 < p < 0.10$). Decreases in hematocrit, presumably dilutional, have been reported with many other drugs that block α_1 -adrenergic receptors. There was no apparent clinical significance of the observed changes in the few patients meeting these criteria.

ECG Changes

Of the ECG parameters monitored during placebo-controlled premarketing studies with nefazodone, a pooled analysis revealed a statistically significant difference between nefazodone and placebo for sinus bradycardia, i.e., 1.5% of nefazodone patients met criteria for a potentially important decrease in heart rate (≤ 50 bpm and a decrease of ≥ 15 bpm) compared to 0.4% of placebo patients ($p < 0.05$). There was no obvious clinical significance of the observed changes in the few patients meeting these criteria.

Other Events Observed During the Premarketing Evaluation of SERZONE

During its premarketing assessment, multiple doses of SERZONE (nefazodone hydrochloride) were administered to 3496 patients in clinical studies, including more than 250 patients treated for at least one year. The conditions and duration of exposure to SERZONE varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies. Unwanted events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of unwanted events into a smaller number of standardized event categories.

In the tabulations that follow, reported adverse events were classified using standard COSTART-based Dictionary terminology. The frequencies presented, therefore, represent the proportion of the 3496 patients exposed to multiple doses of SERZONE who experienced an event of the type cited on at least one occasion while receiving SERZONE. All reported events are included except those already listed in the Treatment-Emergent Adverse Experience Incidence table, those events listed in other safety-related sections of this insert, those adverse experiences subsumed under COSTART terms that are either overly general or excessively specific so as to be uninformative, those events for which a drug cause was very remote, and those events which were not serious and occurred in fewer than two patients.

It is important to emphasize that, although the events reported occurred during treatment with SERZONE, they were not necessarily caused by it.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.

Body as a whole—*Infrequent*: allergic reaction, malaise, photosensitivity reaction, face edema, hangover effect, abdomen enlarged, hernia, pelvic pain, and halitosis. *Rare*: cellulitis.

Cardiovascular system—*Infrequent*: tachycardia, hypertension, syncope, ventricular extrasystoles, and angina pectoris. *Rare*: AV block, congestive heart failure, hemorrhage, pallor, and varicose veins.

Dermatological system—*Infrequent*: dry skin, acne, alopecia, urticaria, maculopapular rash, vesiculobullous rash, and eczema.

Gastrointestinal system—*Frequent*: gastroenteritis. *Infrequent*: eructation, periodontal abscess, abnormal liver function tests, gingivitis, colitis, gastritis, mouth ulceration, stomatitis, esophagitis, peptic ulcer, and rectal hemorrhage. *Rare*: glossitis, hepatitis, dysphagia, gastrointestinal hemorrhage, oral moniliasis, and ulcerative colitis.

Hemic and lymphatic system—*Infrequent*: ecchymosis, anemia, leukopenia, and lymphadenopathy.

Metabolic and nutritional system—*Infrequent*: weight loss, gout, dehydration, lactic dehydrogenase increased, SGOT increased, and SGPT increased. *Rare*: hypercholesterolemia and hypoglycemia.

Musculoskeletal system—*Infrequent*: arthritis, tenosynovitis, muscle stiffness, and bursitis. *Rare*: tendinous contracture.

Nervous system—*Infrequent*: vertigo, twitching, depersonalization, hallucinations, suicide attempt, apathy, euphoria, hostility, suicidal thoughts, abnormal gait, thinking abnormal, attention decreased, derealization, neuralgia, paraneoplastic reaction, dysarthria, increased libido, suicide, and myoclonus. *Rare*: hyperkinesia, increased salivation, cerebrovascular accident, hyperesthesia, hypotonia, ptosis, and neuroleptic malignant syndrome.

Respiratory system—*Frequent*: dyspnea and bronchitis. *Infrequent*: asthma, pneumonia, laryngitis, voice alteration, epistaxis, hiccup. *Rare*: hyperventilation and yawn.

Special senses—*Frequent*: eye pain. *Infrequent*: dry eye, ear pain, abnormality of accommodation, diplopia, conjunctivitis, mydriasis, keratoconjunctivitis, hyperacusis, and photophobia. *Rare*: deafness, glaucoma, night blindness, and taste loss.

Urogenital system—*Frequent*: impotence^a. *Infrequent*: cystitis, urinary urgency, metrorrhagia^a, amenorrhea^a, polyuria, vaginal hemorrhage^a, breast enlargement^a, menorrhagia^a, urinary incontinence, abnormal ejaculation^a, hematuria, nocturia, and kidney calculus. *Rare*: uterine fibroids enlarged^a, uterine hemorrhage^a, anorgasmia, and oliguria.

^aAdjusted for gender.

Postintroduction Clinical Experience

Postmarketing experience with SERZONE has shown an adverse experience profile similar to that seen during the premarketing evaluation of nefazodone. Voluntary reports of adverse events temporally associated with SERZONE have been received since market introduction that are not listed above and for which a causal relationship has not been established. These include:

Rare occurrences of convulsions (including grand mal seizures) and priapism (see PRECAUTIONS section);
Rare reports of rhabdomyolysis involving patients receiving the combination of SERZONE and lovastatin or simvastatin (see PRECAUTIONS section);
Rare reports of liver necrosis and liver failure, in some cases leading to liver transplantation and/or death.

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class

SERZONE (nefazodone hydrochloride) is not a controlled substance.

Physical and Psychological Dependence

In animal studies, nefazodone did not act as a reinforcer for intravenous self-administration in monkeys trained to self-administer cocaine, suggesting no abuse liability. In a controlled study of abuse liability in human subjects, nefazodone showed no potential for abuse.

Nefazodone has not been systematically studied in humans for its potential for tolerance, physical dependence, or withdrawal. While the premarketing clinical experience with nefazodone did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior, it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of SERZONE (e.g., development of tolerance, dose escalation, drug-seeking behavior).

OVERDOSAGE

Human Experience

In premarketing clinical studies, there were seven reports of nefazodone overdose alone or in combination with other pharmacological agents. The amount of nefazodone ingested ranged from 1000 mg to 11,200 mg. Commonly reported symptoms from overdose of nefazodone included nausea, vomiting, and somnolence. One nonstudy participant took 2000–3000 mg of nefazodone with methocarbamol and alcohol; this person reportedly experienced a convulsion (type not documented). None of these patients died.

In postmarketing experience, overdose with SERZONE alone and in combination with alcohol and/or other substances has been reported. Commonly reported symptoms were similar to those reported from overdose in premarketing experience. While there have been rare reports of fatalities in patients taking overdoses of nefazodone, predominantly in combination with alcohol and/or other substances, no causal relationship to nefazodone has been established.

Overdosage Management

Treatment should consist of those general measures employed in the management of overdosage with any antidepressant.

Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients.

Activated charcoal should be administered. Due to the wide distribution of nefazodone in body tissues, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for nefazodone are known.

In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians' Desk Reference (PDR).

DOSAGE AND ADMINISTRATION

Initial Treatment

The recommended starting dose for SERZONE (nefazodone hydrochloride) is 200 mg/day, administered in two divided doses (BID). In the controlled clinical trials establishing the antidepressant efficacy of SERZONE, the effective dose range was generally 300 to 600 mg/day. Consequently, most patients, depending on tolerability and the need for further clinical effect, should have their dose increased. Dose increases should occur in increments of 100 mg/day to 200 mg/day, again on a BID schedule, at intervals of no less than 1 week. As with all antidepressants, several weeks on treatment may be required to obtain a full antidepressant response.

Dosage for Elderly or Debilitated Patients

The recommended initial dose for elderly or debilitated patients is 100 mg/day, administered in two divided doses (BID). These patients often have reduced nefazodone clearance and/or increased sensitivity to the side effects of CNS-active drugs. It may also be appropriate to modify the rate of subsequent dose titration. As steady-state plasma levels do not change with age, the final target dose based on a careful assessment of the patient's clinical response may be similar in healthy younger and older patients.

Maintenance/Continuation/Extended Treatment

There is no body of evidence available from controlled trials to indicate how long the depressed patient should be treated with SERZONE. It is generally agreed, however, that pharmacological treatment for acute episodes of depression should continue for up to 6 months or longer. Whether the dose of antidepressant needed to induce remission is identical to the dose needed to maintain euthymia is unknown. Systematic evaluation of the efficacy of SERZONE has shown that efficacy is maintained for periods of up to 36 weeks following 16 weeks of open-label acute treatment (treated for 52 weeks total) at dosages that averaged 438 mg/day. For most patients, their maintenance dose was that associated with response during acute treatment. (See CLINICAL PHARMACOLOGY section.) The safety of SERZONE in long-term use is supported by data from both double-blind and open-label trials involving more than 250 patients treated for at least one year.

Switching Patients to or from a Monoamine Oxidase Inhibitor

At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with SERZONE. In addition, at least 7 days should be allowed after stopping SERZONE before starting an MAOI.

HOW SUPPLIED

SERZONE® (nefazodone hydrochloride) tablets are hexagonal tablets imprinted with BMS and the strength (i.e., 100 mg) on one side and the identification code number on the other. The 100 mg and 150 mg tablets are bisect scored on both tablet faces. The 50 mg, 200 mg, and 250 mg tablets are unscored.

NDC CODE	DESCRIPTION
NDC 0087-0031-47	50 mg light pink tablet, bottle of 60
NDC 0087-0032-31	100 mg white tablet, bottle of 60
NDC 0087-0039-31	150 mg peach tablet, bottle of 60
NDC 0087-0033-31	200 mg light yellow tablet, bottle of 60
NDC 0087-0041-31	250 mg white tablet, bottle of 60

U.S. Patent No. 4,338,317

Store at room temperature, below 40° C (104° F) and dispense in a tight container.

REFERENCES

1. HALCION® and XANAX® are registered trademarks of the Upjohn Company.
2. SELDANE® is a registered trademark of Merrell Pharmaceuticals, Incorporated, a subsidiary of Hoechst Marion Roussel.
3. HISMANAL® and PROPULSID® are registered trademarks of Janssen Pharmaceutica, Incorporated.
4. ORAP® is a registered trademark of Gate Pharmaceuticals, a division of Teva Pharmaceuticals USA.
5. TEGRETOL® is a registered trademark of Novartis Corporation.



Bristol-Myers Squibb Company
Princeton, NJ 08543 U.S.A.

Revised June 2000
0032D1M-15
D5-B001-08-00

Printed in USA
P4460-13

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-152/S-006

MEDICAL REVIEW

Review and Evaluation of Clinical Data

NDA: 20-152
DRUG: SERZONE® (Nefazodone HCl) Tablets
MATERIAL PROVIDED: Labeling Submission - SLR 006
SPONSOR: Bristol-Myers Squibb
CORRESPONDENCE DATE: 5/26/00
DATE RECEIVED: 5/30/00

I: REVIEW:

The sponsor is submitting the labeling change we requested in our 3/27/98 letter with one exception. They wish to add the contraindication along with other contraindicated drugs

Please see the described labeling change attached to this review.

II. RECOMMENDATION:

I recommend the labeling be accepted.

Earl D. Hearst, M.D.
Medical Reviewer
HFD-120

cc:file\tlaughren\ehearst\pdavid.

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER: 20-152/S-006

ADMINISTRATIVE DOCUMENTS

**REGULATORY PROJECT MANAGER
LABELING REVIEW**

NDA: 20-152
Sponsor: Bristol-Myers Squibb (BMS)
DRUG: Serzone (nefazodone hydrochloride) 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg Tablets
Supplements: SLR-006
History of Submissions:

- Original submission dated 8-8-96
- Agency issues an approvable letter dated 3-27-98
- BMS amends the supplement in a submission dated 10-6-98
- Agency issues a second approvable letter dated 3-29-00
- BMS amends the supplement in a submission dated 5-26-00

Notes of interest:

- The last approved labeling supplement was S-023 (approval letter dated 6-1-00).

REVIEW

20-152/SLR-006

Dated: 8-9-96 and amended on 10-6-98 and 5-26-00

CBE: No

Label Code:1017710A8

Reviewed by Medical Officer and OCPB: Yes, acceptable.

The supplement provides for the following revisions to labeling:

1. The addition of "carbamazepine" to the list of drugs contraindicated with nefazodone in the **CONTRAINDICATIONS** section of labeling.
2. A new subsection in the **PRECAUTIONS** section entitled **Interaction with Carbamazepine**.
3. Revisions to the **Pharmacokinetics-Protein Binding** and the **Precautions-Drug Interactions** sections based upon information derived from *in vivo* studies to examine the effects of nefazodone on the pharmacokinetics of warfarin, fluoxetine, phenytoin, desipramine, lithium, carbamazepine, and theophylline.

Note: All of these revisions were made verbatim as outlined in the Agency letter dated 3-27-98 except for one minor editorial change in the **CONTRAINDICATIONS** section. BMS included carbamazepine in the list of drugs whose use is contraindicated versus

CONCLUSIONS

1. This supplement only provides for the labeling revisions listed above. Please see attached documentation denoting the revisions made to labeling compared to the last approved labeling for nefazodone (SLR-023; approval letter dated 6-1-00).
2. I noted, during the course of my labeling review, that carbamazepine was not included in the list of drugs which should not be taken with Serzone in the

NDA 20-152

Page 2

PRECAUTIONS-Information for Patients-Concomitant Medication section of labeling. I recommend that the sponsor be requested to add this at the next printing of labeling.

3. I recommend that an approval letter issue for the above supplemental application.

Paul David, RPh
Regulatory Project Manager

John Purvis
Supervisory Consumer Safety Officer

NDA 20-152
HFD-120/Div File
HFD-120/TLaughren/EHearst/PDavid
7-17-00
LABELING REVIEW